Research programme: fibrotic disease therapeutics - Evotec SE/Fibrocor
Latest Information Update: 27 Sep 2023
At a glance
- Originator Fibrocor Therapeutics
- Developer Evotec SE; Fibrocor Therapeutics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Fibrosis